Bridging live-cell imaging and next-generation cancer treatment
M Alieva, AKL Wezenaar, EJ Wehrens… - Nature Reviews Cancer, 2023 - nature.com
By providing spatial, molecular and morphological data over time, live-cell imaging can
provide a deeper understanding of the cellular and signalling events that determine cancer …
provide a deeper understanding of the cellular and signalling events that determine cancer …
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Synthetic immunity to cancer has been pioneered by the application of chimeric antigen
receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable …
receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable …
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1
B Miao, Z Hu, R Mezzadra, L Hoeijmakers, A Fauster… - Cancer cell, 2023 - cell.com
The dysregulated expression of immune checkpoint molecules enables cancer cells to
evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 …
evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 …
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2
Cancer immunotherapy aims to initiate or amplify immune responses that eliminate cancer
cells and create immune memory to prevent relapse. Immune checkpoint inhibitors (ICIs) …
cells and create immune memory to prevent relapse. Immune checkpoint inhibitors (ICIs) …
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells
AZ Gad, JS Morris, L Godret-Miertschin… - Science …, 2025 - science.org
Chimeric antigen receptor T cells (CART) targeting CD19 through CD28. ζ signaling induce
rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB. ζ …
rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB. ζ …
Four challenges to CAR T cells breaking the glass ceiling
Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic
efficacy in the clinic and can even mediate curative responses in patients with hematologic …
efficacy in the clinic and can even mediate curative responses in patients with hematologic …
New insights into CAR T cell-mediated killing of tumor cells
D Espie, E Donnadieu - Frontiers in Immunology, 2022 - frontiersin.org
Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors
(CAR) has demonstrated striking efficacy for the treatment of several hematological …
(CAR) has demonstrated striking efficacy for the treatment of several hematological …
Potency assays and biomarkers for cell-based advanced therapy medicinal products
C Capelli, C Cuofano, C Pavoni, S Frigerio… - Frontiers in …, 2023 - frontiersin.org
Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro,
with or without genetic modification, is a rapidly growing area of drug development, even …
with or without genetic modification, is a rapidly growing area of drug development, even …
[HTML][HTML] Detection of aberrant CD58 expression in a wide spectrum of lymphoma subtypes: implications for treatment resistance
S Younes, S Zhao, S Bharadwaj, AP Mosquera… - Modern Pathology, 2023 - Elsevier
CD58 or lymphocyte function–associated antigen-3, is a ligand for CD2 receptors on T and
NK cells and is required for their activation and target cell killing. We recently showed a …
NK cells and is required for their activation and target cell killing. We recently showed a …
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling
Chimeric antigen receptor (CAR) T cells used for the treatment of B cell malignancies can
identify T cell subsets with superior clinical activity. Here, using infusion products of …
identify T cell subsets with superior clinical activity. Here, using infusion products of …